the world's First
Triple Agonist
Retatrutide is the only medication that acts at 3 different receptors:
GIP, GLP-1, and Glucagon.
Head to head
competition
Other weight-loss drugs have entered the market, including Ozempic (semaglutide) and Mounjaro (tirzepatide).Retatrutide is rumored to beat them all.
research
Retatrutide first entered clinical trials in 2021. It is expected to enter Phase 3 trials in 2023.
name
LY3437943
Retatrutide was developed under the name LY3437943. It also is referred to as GGG, after it's triple-agonist activity. It will be assigned a trade name if authorized by the FDA.
early access
Be the first to know about new developments, press releases, and FDA authorization.
Thank you
Watch for news over the next 12 months.